Sanofi joins pack to reduce insulin costs, cutting US Lantus list price by 78%

Following announcements in in the last few days, first by Eli Lilly (NYSE: LLY) and then by Novo Nordisk (NOV: N), French pharma major Sanofi (Euronext: SAN) revealed that it too would slash the US price of its insulin products

Sanofi said it will cut the list price of Lantus (insulin glargine injection) 100 Units/mL, its most widely prescribed insulin in the USA, by 78%. The company also will establish a $35 cap on out-of-pocket costs for Lantus for all patients with commercial insurance, underscoring its longstanding commitment to offer affordable access to medicines.

These moves, which go into effect January 1, 2024, will come in addition to decisions taken in June 2022 to lower diabetes medicines costs: the launch of an unbranded Lantus biologic at -60% versus Lantus list price, and a cap on out-of-pocket costs on insulin to $35 for all people without insurance. With all those decisions, now Sanofi’s suite of savings programs ensures that no patient will pay more than $35 for a monthly supply of Lantus. Finally, Sanofi will also cut the list price of its short-acting Apidra (insulin glulisine injection) 100 Units/mL by 70%.